Rapid, Agonist-dependent Phosphorylation in Vivo of Human Thromboxane Receptor Isoforms
MINIMAL INVOLVEMENT OF PROTEIN KINASE C*

(Received for publication, October 7, 1996, and in revised form, December 5, 1996)

Aïda Habib Dagger , Roberta Vezza Dagger , Christophe Créminon §, Jacques Maclouf and Garret A. FitzGerald Dagger par

From the Dagger  Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, § Commissariat à l'Energie Atomique (Saclay), Service de Pharmacologie et d'Immunologie, Saclay 91191 Gif-sur-Yvette, France, and  INSERM U 348, Hôpital Lariboisière, 75475 Paris Cedex 10, France

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

Thromboxane A2 (TxA2) is a potent vasoconstrictor and platelet agonist. Its biological function is tightly regulated. G protein-coupled membrane receptors transduce the effects of TxA2. However, although a single thromboxane receptor (TP) gene has been identified, two splice variants have been cloned from human placenta and megakaryocytic lines (TPalpha ) and from human endothelial cells (TPbeta ). These differ in the length of their carboxyl-terminal extensions (15 versus 79 residues), which contain multiple potential sites for receptor phosphorylation. Given that TP agonists activate protein kinase C (PKC), it would seem possible that PKC-dependent phosphorylation of TPs might play a central role in homologous desensitization of these receptors.

To determine if the TP isoforms were differentially phosphorylated in response to agonist in vivo, human embryonic kidney (HEK) 293 cells were stably transfected with TPalpha and TPbeta . Isoform-specific anti-peptide antibodies were developed and used to immunoprecipitate the phosphorylated receptors. U46619, a PGH2/TxA2 mimetic, induced specific phosphorylation of both isoforms. Phosphorylation of the two isoforms was similar in dose and time dependence, reaching a plateau at around 100 nM U46619. Inhibition of PKC with either GF 109203X (5 µM) or RO 31-8220 (5 µM) or of protein kinase A with H-89 (50 µM) marginally influenced agonist-dependent phosphorylation of either isoform and failed to modulate homologous desensitization of agonist-induced stimulation of inositol phosphate formation. Similar results were obtained when PKC was down-regulated by long term incubation with the phorbol ester, phorbol myristate acetate. Although short term stimulation with phorbol myristate acetate caused PKC-dependent phosphorylation of TPs in vivo, thrombin stimulation of the TP-transfected HEK cells in vivo failed to phosphorylate either of the TP isoforms. Thus, despite the capacity of PKC to phosphorylate TPs in HEK 293 cells and the likely activation of PKC by TP stimulation, this enzyme, like protein kinase A, contributes marginally to rapid, agonist-induced phosphorylation of either TP isoform.


INTRODUCTION

Thromboxane A2 (TxA2)1 is a product of the sequential metabolism of arachidonic acid by the cyclooxygenases and TxA2 synthase (1). It is formed upon activation of a variety of cells, including platelets, macrophages, and vascular smooth muscle cells and exhibits potent biological activity, causing platelet aggregation and secretion, mitogenesis, and vasoconstriction (2, 3). These effects are transduced via membrane receptors, identified initially with a variety of diverse structural ligands (4). Although such pharmacological studies suggested diversity among thromboxane receptors (TPs), a single gene, encoding a member of the heptahelical G protein-coupled receptor (GPCR) family, has been cloned (5). However, two variants, based on alternative splicing of the carboxyl-terminal tail of the receptor, have been identified. The first, TPalpha , was cloned from a cDNA library derived from placental (6) and also from megakaryocytic cell lines (7, 8). The second, TPbeta , was cloned from a human umbilical endothelial cell cDNA library (9). The precise biological functions subserved by these isoforms is presently unknown. For example, mRNAs for both isoforms exist in human platelets (10); however, it is unknown whether they represent the two forms of functional TPs identified by ligand binding in human platelets (11). Similarly, the functional response to TP stimulation in endothelial cells remains ill defined. The capacity of the isoforms to subserve distinct biological functions is illustrated by differential coupling of the expressed isoforms to adenylate cyclase in COS cells (10).

One aspect of TP function that, a priori, may differ between the isoforms is agonist-dependent desensitization. TPbeta differs from the a isoform in having a longer (79 versus 15 amino acids) carboxyl-terminal extension, which contains an additional 11 serine and 4 threonine residues. It also contains a tyrosine residue, absent from the TPalpha isoform (9). These amino acids are potential targets for phosphorylation, which is likely to be intrinsic to the process of desensitization. Given the rapid formation of TxA2 by activated cells and its potency, regulation of the response to this eicosanoid by homologous receptor desensitization is of likely biological importance. Biosynthesis of additional ligands, such as thrombin and growth factors (12-16) may amplify the response to TxA2, perhaps via cross-talk with TPs. Similarly, TxA2 may evoke formation of counterregulatory ligands, such as prostacyclin, which may also modulate TP function (17).

Presently, our understanding of the molecular events that underlie TP desensitization in intact cells is limited. These have largely been confined to pharmacological studies (18), which suggest differences between cells but have not discriminated between the cloned isoforms. We have previously demonstrated (19) that a fusion protein, including the carboxyl-terminal tail of the TPalpha , may be phosphorylated by purified PKC and, to a lesser extent, PKA, in vitro. Okwu et al. (20) have provided evidence that TPs in human platelets may be subject to phosphorylation.

We now report the characterization of specific, peptide-based antibodies to TPalpha and TPbeta and demonstrate that both receptor isoforms are predominantly localized at the plasma membrane of human embryonic kidney (HEK) 293 cells stably overexpressing TP receptors. Both isoforms are phosphorylated in response to stimulation with the prostaglandin H2/TxA2 mimetic, U46619 (21). Interestingly, the dose and time dependence of agonist-induced receptor phosphorylation appeared similar for both isoforms in vivo, and neither PKC nor PKA played a major role in this phenomenon.


EXPERIMENTAL PROCEDURES

Materials

The cDNAs for the TP isoforms were kindly provided by Dr. Colin Funk and Dr. J. Anthony Ware, respectively. The cDNA and the antibody for human thrombin receptor were kindly provided by Dr. Lawrence Brass. [32P]Orthophosphate (~6,000-7,000 Ci/mmol), myo-[2-3H]inositol (18.3 Ci/mmol) and 14C-protein molecular weight markers were purchased from Amersham Corp. [3H]SQ29,548 (46 Ci/mmol) was obtained from DuPont NEN. pcDNA3 was obtained from Invitrogen (San Diego, CA). HEK 293 cells were obtained from ATCC (Rockville, MD). CNBr-activated Sepharose and E-Z-SEP® polyclonal kit were obtained from Pharmacia Biotech Inc. Geniticin (G418, specific activity at 750 µg/mg) and all tissue culture media were purchased from Life Technologies, Inc. Phorbol 12-myristate 13-acetate (PMA), bovine alpha -thrombin (285 units/mg of protein), forskolin (FK), dibutyryl cAMP (Bt2cAMP), 3-isobutyl-1-methylxanthine (IBMX), sodium orthovanadate, sodium fluoride, sodium pyrophosphate, ATP, sodium deoxycholate, and protease inhibitors were purchased from Sigma, and N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide (H-89 dihydrochloride) and 4alpha -PMA were from Biomol Research Laboratories (Plymouth Meeting, PA). RO-31-8220 and bisindolylmaleimide I (GF 109203X) were from Calbiochem. 9,11-Dideoxy-9alpha ,11alpha -methanoepoxyprostaglandin F2alpha (U46619) and SQ29,548 were obtained from Cayman Chemical Co., Inc. (Ann Arbor, MI). Anion exchange resin AG 1X-8 (formate form, 200-400 mesh) was from Bio-Rad. All electrophoresis reagents were from J. T. Baker (Phillipsburg, NJ).

Stable Expression of Human Thromboxane A2 Receptors in HEK 293 Cells

The cDNA encoding the TPalpha isoform was subcloned into the EcoRI-XbaI sites of the mammalian expression vector pcDNA3. The cDNA for the TPbeta isoform subcloned into the EcoRI-EcoRI sites of the same vector (22) was further digested by BamHI and Bsu36I and then ligated after creating a blunt end. This treatment resulted in the truncation of 195 base pairs in the 5'-untranslated region, leaving one ATG start codon. This enhanced the expression of the receptors in stably transfected cells 4-5-fold relative to the undigested construct (data not shown). Following truncation, the stably transfected HEK 293 cells expressed similar amounts of the TPalpha and TPbeta isoforms as assessed by binding studies (see "Results").

HEK 293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, 2 mM glutamine, 50 units/ml penicillin, 100 µg/ml streptomycin. HEK 293 cells stably overexpressing both isoforms were prepared as described previously (22). Briefly, cells were plated at 0.7 × 106 cells/100-mm culture dish and transfected with 10 µg of TPalpha -pcDNA3, TPbeta -pcDNA3, or pcDNA3 using a cationic liposome-mediated transfer according to the manufacturer's instructions (DOTAP; Boehringer Mannheim). After 8 h of transfection, the culture medium was changed, and selection of the clones was performed in the presence of 1 mg/ml Geneticin (G418). Receptor expression was assessed by binding of the specific TP antagonist [3H]SQ29,548 as well as by the agonist (U46619)-stimulated increase in total inositol phosphate formation.

Binding Assays

Binding of [3H]SQ29,548 was performed on intact cells as follows. Briefly, subconfluent adherent cells in 24-well plates (2.5 × 105 cells) were incubated for 30 min at 37 °C in 250 µl of serum-free DMEM, 0.2% bovine serum albumin (BSA) in the presence of increasing concentrations of [3H]SQ29,548. Cells were washed twice in ice-cold phosphate-buffered saline (PBS), containing 0.02% BSA and lysed in 0.5 N NaOH. The protein content was determined by micro-BCA® assay (Pierce) with the microbicinchoninic acid reagent and BSA as a standard. Cell number was assessed in parallel wells. Nonspecific binding was determined by the addition of 10 µM unlabeled SQ29,548 and did not exceed 5-10% of the total binding.

Alternatively, crude membrane fractions were prepared as described (19) with minor modifications. Briefly, cells at confluence in 100-mm dishes were scraped in Hepes buffer (10 mM Hepes, pH 7.6, containing 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, and 10 µM indomethacin), sonicated, and centrifuged for 15 min at 1,000 × g at 4 °C. Supernatants were further centrifuged at 125,000 × g at 4 °C for 1 h, and pellets were resuspended in the same buffer, containing 10% glycerol and 100 mM NaCl. Radioligand binding was performed using 50 µg of membrane protein and increasing concentrations of [3H]SQ29,548. Reactions were carried out in a total volume of 100 µl at 4 °C for 2 h. The reaction was stopped with 4 ml of 10 mM Tris, pH 7.4, followed by filtration through Whatman GF/C glass filters. Filters were subsequently washed twice with the same buffer and counted for radioactivity. Nonspecific binding was determined in the presence of excess unlabeled SQ29,548 (25 µM). It did not exceed 15% of the total binding. For competition binding experiments, 50 µg of membrane protein was incubated with 40 nM [3H]SQ29,548 and increasing concentrations of U46619 (0.1-30 µM). Reactions were carried out under the same conditions as above. The data were subject to Scatchard analysis, and an apparent Kd and Bmax were determined using a computer program (Radlig Biosoft®, Cambridge, UK). The same program was used for analysis of the competition experiments and for calculation of Ki values for U46619.

Total Inositol Phosphate Formation

Inositol phosphate formation was measured as described previously (23). Briefly, confluent cells (4-5 × 105 cells in 12-well plates) were labeled with 2 µCi of myo-[2-3H]inositol (18.3 Ci/mmol) for 20-24 h in serum-free, inositol-free DMEM, containing 0.5% BSA, 20 mM Hepes. The culture medium was changed, and cells were incubated in the same medium containing 20 mM LiCl. After a 10-min incubation, U46619 was added for 10 min unless otherwise indicated. When SQ29,548 was used, it was added for 10 min prior to the addition of U46619. The reaction was stopped by aspiration of the supernatant and the addition of 0.75 ml of 10 mM formic acid. After incubation for 30 min at room temperature, the solution was collected in 3 ml of 5 mM ammonia hydroxide, giving a pH of 8.5-9. Samples were subjected to an anion exchange AG 1X-8 column. Free inositol and glycerophosphoinositol were washed with a 40 mM concentration of a formate/formic acid buffer, pH 5. Total inositol phosphates were eluted with 4 ml of the 2 M formate/formic acid buffer from which 1 ml was counted. Results were expressed as a percentage of the increase in agonist-stimulated total inositol phosphate formation compared with unstimulated cells.

Ca2+ Release

Intracellular Ca2+ levels ([Ca2+]i) were measured in TPalpha - or TPbeta -transfected HEK 293 cells in suspension as described previously (24). Briefly, cells were washed twice with PBS, loaded for 1 h at 37 °C with 5 µM Fura-2/AM (Molecular Probes, Eugene, OR) in phenol red free-RPMI 1640 culture media. Cells were further washed and incubated for 5 min in PBS, containing 1 mM EDTA and 5 mM EGTA, harvested, washed again, and resuspended at 106 cells/ml in RPMI 1640. Cells were allowed to sit for 1 h. Fluorescence was detected in suspended cells diluted at 106 cells/ml, using an SLM/Aminco AB2 spectrophotometer (Urbana, CA), and approximate values of [Ca2+]i were calculated using a Kd of 224 nM for Fura-2.

Cells (1 × 106/ml, 1.5 ml) were incubated with 1 µM U46619 for the indicated times in the desensitization experiments. They were then washed and further stimulated with 300 nM U46619. Control cells were treated with vehicle (i.e. ethanol, 0.01%) alone and further assessed in parallel for mobilization of [Ca2+]i.

Generation of Specific Anti-peptide Antibodies

Rabbit polyclonal antibodies were raised to immunoprecipitate the TP receptor isoforms. These were directed against the last 15 amino acids of the carboxyl-terminal ends of the isoforms: NH2-SLSLQPQLTQRSGLQ-COOH (amino acid sequence 327-341, referred to as Abalpha ) for TPalpha and NH2-(C)PFEPPTGKALSRKD-COOH (amino acid sequence 355-369, referred to as Abbeta ) for TPbeta . The extra cysteine residue was added in the TPbeta peptide to allow coupling to BSA and acetylcholinesterase (see below). Immunization procedures and the generation of peptides were performed as described previously (25). Boosters were administered every 2 months. Sera from the same rabbit and within the same booster were pooled and kept sterile at 4 °C in the presence of 0.01% sodium azide. The titer of the different sera was tested in a competitive enzyme immunoassay, using the corresponding TP receptor peptides covalently linked to acetylcholinesterase. The antisera Abalpha and Abbeta had titers of 1/5000-1/10000 and 1/3000-1/5000, respectively. Immunoaffinity columns of each antibody were prepared for immunoprecipitation analysis. Antisera were first partially purified using the E-Z-SEP® kit (Pharmacia) and further incubated with CNBr-activated Sepharose according to the manufacturer's instructions. Normal rabbit immunoglobulins, coupled to CNBr-activated Sepharose, were used for preclearing of cell lysates.

Immunoblot analysis of total cell lysates or of the immunoprecipitates was performed to characterize the antibodies. Cell membranes were prepared as described previously, and 50 µg were mixed with 1 volume of 2 × Laemmli buffer (1 × Laemmli buffer: 4% SDS, 5% glycerol, 60 mM Tris, pH 6.8, and 0.005% bromphenol blue) under reducing conditions (75 mM dithiothreitol) and vortexed. Samples were treated under nonreducing conditions for the immunoprecipitation experiments. SDS-polyacrylamide gel electrophoresis was performed using 10% acrylamide for the separating gel. Proteins were electrotransferred onto nitrocellulose membranes (Schleicher and Schuell, Keene, NH). Blots were saturated for 2 h in Tris-buffered saline (50 mM Tris, pH 7.5, 250 mM NaCl, 0.1% Tween 20) containing 2% BSA. Membranes were further incubated overnight at 4 °C with Abalpha (1/2000) or Abbeta (1/1000) in Tris-buffered saline containing 0.5% BSA. Membranes were washed five times for 10 min in the same buffer without BSA and incubated for 1 h at room temperature with a 1/5000 dilution of a donkey anti rabbit antibody coupled to horseradish peroxidase (Jackson ImmunoResearch, West Grove, Pa). Excess antibody was washed, and positive bands were revealed by ECL (Amersham) according to the manufacturer's instructions.

Immunofluorescence Staining

HEK 293 cells overexpressing TP receptor isoforms were subcultured in a two-well Lab-Tek slide culture chamber (Nunc, Naperville, IL) coated with 10 µg/ml of human fibronectin (Life Technologies, Inc.). Subconfluent cells were washed once with PBS buffer and fixed in 100% methanol. Fixed specimens were blocked for 30 min at room temperature in PBS containing 2% BSA. Specimens were incubated with the receptor antibodies (diluted at 1/1000 for Abalpha and 1/500 for Abbeta ) in PBS, containing 0.5% BSA for 1 h at room temperature followed by fluorescein isothiocyanate-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch) at a dilution of 1/1000 in the same PBS solution. Slides were mounted in a mounting solution (Vector Laboratories Inc., Burlingame, CA). Immunofluorescence staining was examined by an Olympus® inverted fluorescence microscopy.

Phosphorylation of Intact Cells

Whole cell phosphorylation was performed as described (26) with minor modifications. Briefly, subconfluent cells in 60-mm dishes (2-3 × 106 cells) were washed once in phosphate-free DMEM media, containing 20 mM Hepes, 0.5% BSA as above. Cells were further incubated for 45 min in the same medium, containing 100 µCi/ml of [32P]orthophosphate (6,000-7,000 Ci/mmol). Kinase inhibitors, SQ29,548, or vehicle were added during the labeling period. Stimuli or vehicle were added for 10 min, unless otherwise indicated. Me2SO and ethanol concentrations did not exceed 0.1% and did not modify the pattern of phosphorylation of the TP isoforms. The reaction was quenched by transferring the dishes on ice and aspirating the supernatants. Cells were washed with 2 ml of ice-cold PBS/dish and lysed with 0.8 ml of radioimmune precipitation buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40 (v/v), 0.5% sodium deoxycholate (w/v), 0.1% SDS (w/v) containing 10 mM sodium fluoride, 25 mM sodium pyrophosphate, 10 mM ATP, 1 µg/ml leupeptin, 10 µg/ml soybean trypsin inhibitor, 1 mM benzamidine hydrochloride, and 0.5 mM phenylmethylsulfonyl fluoride). Cells were scraped with a rubber policeman after 15 min on ice, passed through a 231/2 gauge needle, and centrifuged for 15 min at 10,000 × g at 4 °C. Supernatants were collected, and total cell protein was measured by micro BCA®, using BSA as a standard. Lysates (0.8 mg of total cell protein in 0.8 ml) were precleared for 1 h at 4 °C with 50 µl of normal rabbit IgG covalently coupled to Sepharose CL-4B. The preclearing step was critical in the phosphorylation assays, since it removed a phosphorylated doublet, which migrates at the same molecular weight as the TP isoforms.

Samples were centrifuged for 3 min at 10,000 × g, and supernatants were further immunoprecipitated overnight at 4 °C using 50 µl of immunoaffinity Sepharose for either Abalpha or Abbeta , as described above. The beads were washed four times with 1 ml of radioimmune precipitation buffer and resuspended in 100 µl of 1 × Laemmli buffer under nonreducing conditions. Samples were vigorously vortexed for 15 min, centrifuged for 5 min at 10,000 × g, and loaded onto SDS-polyacrylamide gels, as described above. Quantitative analysis of radioactivity in the samples was performed using a PhosphorImagerTM 445-SI (Molecular Dynamics Inc., Sunnyvale, CA) after the gels were dried. Identical areas were integrated, and results were represented as percentages of the control values.


RESULTS

Characterization of the HEK 293 Cells Overexpressing the TP Isoforms

To determine whether TPalpha or TPbeta couples differentially to downstream signals, we developed HEK 293 cells stably overexpressing both isoforms. Normal HEK 293 cells as well as cells transfected with the pcDNA3 vector alone (HEK 293-VEC) showed no detectable amounts of endogenous TPs in binding assays. Among several HEK 293 clones stably overexpressing the receptors, we selected clones that exhibited similar levels of receptors as expressed per number of binding sites per cell or per pmol of receptor per mg of total protein (Table I). The stably overexpressing clones, TPalpha -5 and TPbeta -17, bind [3H]SQ29,548 in a saturable manner. Scatchard analysis revealed similar dissociation constants (Kd) 21.9 ± 2.2 nM and 24.4 ± 1.8 nM for the TPalpha and TPbeta receptor isoforms, respectively (Table I). The binding of [3H]SQ29,548 was displaced with high concentrations of U46619. The Ki values for U46619 were 1.95 ± 0.32 µM (mean ± S.E., n = 4) for TPalpha and 1.17 ± 0.17 µM (mean ± S.E., n = 3) for TPbeta (p value not significant).

Table I.

Binding properties of [3H]SQ29,548 in HEK 293 cells stably overexpressing the human thromboxane receptor TPalpha and TPbeta isoforms

Crude cell membranes were incubated in the presence of increasing amounts of [3H]SQ29,548 for 2 h at 4°C, and binding analysis was performed as described under "Experimental Procedures." Nonspecific binding was determined in the presence of 25 µM unlabeled SQ29,548. Results represent the mean ± S.E. of eight or nine different experiments. When binding experiments were performed on whole cells, TPalpha -5 and TPbeta -17 expressed 2.8 ± 1 × 106 sites/cell (n = 5) and 4.6 ± 0.9 × 106 sites/cell (n = 3), respectively.
Bmax Kd

pmol/mg protein nM
TPalpha -5 1.64  ± 0.2 21.9  ± 2.15
TPbeta -17 1.7  ± 0.26 24.4  ± 1.8

Total Inositol Phosphate Formation and Calcium Release

We assessed the functionality of the expressed isoforms by measurement of agonist-induced total inositol phosphate (IP) formation and calcium mobilization. Both the TPalpha -5 and TPbeta -17 cell lines exhibited an increase in IP formation in the presence of U46619, a prostaglandin H2/TxA2 mimetic. IP formation was similar in the presence (883 ± 33.2 dpm) and the absence of U46619 (901 ± 180 dpm) in HEK 293 cells transfected with the pcDNA3 vector alone and corresponded to values observed in unstimulated TPalpha -5 and TPbeta -17 clones.

The addition of increasing amounts of U46619 (3-3000 nM) for 10 min resulted in a 5-8-fold increase in IP formation, which reached a plateau at around 100 nM for TPalpha and 300 nM for TPbeta (Fig. 1). The EC50 values for U46619 were higher for TPbeta than TPalpha (57 ± 6.7 nM versus 11.1 ± 2 nM, respectively, p < 0.002). U46619 rapidly increased IP formation via both isoforms (4 min). The increase in IP formation was linear up to 60 min (data not shown). Preincubation of either TPalpha -5 or TPbeta -17 with the antagonist SQ29,548 abolished the ability of either to transduce IP formation in response to U46619 stimulation (data not shown).


Fig. 1. Total inositol phosphate formation in response to U46619 in TPalpha - and TPbeta -expressing cells. HEK 293 cells were stably transfected with TPalpha and TPbeta isoforms. Two clones expressing comparable levels of the isoforms were studied in the presence of the prostaglandin H2/TxA2 agonist U46619. TPalpha -5 (bullet ------bullet ) and TPbeta -17 (open circle ------open circle ) cells were labeled with 2 µCi of myo-[2-3H]inositol for 18-24 h. Cells were further incubated with 20 mM Li2+ for 10 min prior to the addition of U46619. The dose-response relationship of U46619 with IP was analyzed after 10 min of incubation. IP formation was analyzed as described under "Experimental Procedures." Results represent the mean ± S.E. of three to five experiments.
[View Larger Version of this Image (13K GIF file)]


When TPalpha -5 and TPbeta -17 were loaded with Fura-2, U46619 induced a rapid increase in intracellular [Ca2+]i (Fig. 2). In TPalpha -5 (Fig. 2A, left part), the increase in [Ca2+]i mobilization was sustained up to 10 min and was dependent on extracellular sources, since chelation of extracellular Ca2+ by pretreating the cells with 2 mM EGTA for 45 s led to a rapid return to the base line. In contrast, U46619 induced a more transient Ca2+ mobilization in TPbeta -17 (Fig. 2B, left part), although the response did not return completely to base line. Basal [Ca2+]i was 46 ± 13 nM (mean ± S.D., n = 21) for TPalpha and 51 ± 18 nM (mean ± S.D., n = 13). For both isoforms, the presence of EGTA depressed Ca2+ mobilization by roughly 60-70%. Thus, Ca2+ mobilization is dependent on extracellular, as well as intracellular, pools of Ca2+. Similarly, preincubation with 1 µM U46619 abolished the increase of Ca2+ in response to a second addition of U46619 in both cell lines (Fig. 2, A and B, right parts). Homologous desensitization of the Ca2+ response to U46619 was demonstrable for concentrations of U46619 as low as 10 nM and for periods of preincubation as short as 2 min (data not shown). No significant increase was observed when cells were incubated with vehicle alone or when they were pretreated with SQ29,548. HEK 293-VEC showed no Ca2+ mobilization (data not shown).


Fig. 2. Effect of U46619 on the [Ca2+]i mobilization in cells expressing TPalpha or TPbeta . A, TPalpha -5 cells; B, TPbeta -17 cells. Left parts, EGTA (2 mM) was added 45 s prior to the addition of U46619. Right parts, cells were incubated for 10 min with 1 µM U46619, washed once, and resuspended at 106 cells/ml. Cells in suspension were incubated with 0.2 µM U46619, and [Ca2+]i release was measured as described under "Experimental Procedures." Basal [Ca2+]i was 46 ± 13 nM (mean ± S.D., n = 21) for TPalpha and 51 ± 18 nM (mean ± S.D., n = 13). The increase in [Ca2+]i was 126 ± 37 nM (mean ± S.D., n = 15) for TPalpha and 236 ± 52 nM (mean ± S.D., n = 13) for TPbeta . These results are representative of four experiments.
[View Larger Version of this Image (18K GIF file)]


Immunoblotting and Immunoprecipitation of the Thromboxane Receptors

Anti-peptide antibodies were raised against amino acid sequences unique to either the human TPalpha or the human TPbeta isoform. Both antibodies demonstrated specific immunoreactivity toward the receptors, as assessed by immunoblot analysis and immunoprecipitation of TPalpha -5 or TPbeta -17. Fig. 3A represents an immunoblot analysis of thromboxane receptors in crude membrane fractions of the TPalpha -5 and TPbeta -17 cells. The antiserum Abalpha reacted with a broad protein band ranging from 55 to 65 kDa in TPalpha -5 (Fig. 3A, lane 2). Similar results were obtained for the Abbeta with the TPbeta -17 membrane fractions (Fig. 3A, lane 4). No immunoreactivity was revealed in membranes from cells transfected with vector alone, by either Abalpha (Fig. 3A, lane 1) or Abbeta (data not shown). Preincubation of the Abalpha or Abbeta with the corresponding peptides suppressed the immunoreactivity in TPalpha -5 (Fig. 3A, lane 3) or TPbeta -17 (Fig. 3A, lane 5), respectively. The Abalpha and Abbeta antibodies did not cross-react (data not shown), indicating their specificity. The capability of these antibodies to immunoprecipitate the TP isoforms was demonstrated using immunoaffinity columns prepared with either Abalpha or Abbeta as described under "Experimental Procedures." Immunoaffinity columns prepared with these antibodies immunoprecipitated a broad protein band from TPalpha -5 and TPbeta -17 (Fig. 3B, lanes 3 and 4, respectively), with an apparent molecular weight similar to that obtained by direct immunoblotting of the membrane fractions. It is important to note that since Abalpha and Abbeta are different sera and could have different characteristics, it is not possible to compare the quantities of the two isoforms that are immunoprecipitated. Similarly, immunoprecipitation of a human platelet cell lysate with the Abalpha revealed a broad protein band with an apparent molecular weight of 45-50 (Fig. 3B, lane 5). No immunoreactivity could be detected when immunoprecipitation of the platelet cell lysate was performed with the Abbeta .


Fig. 3. Immunoblot analysis of TPalpha and TPbeta receptors using anti-peptide antibodies. A, crude membrane fractions (50 µg) of HEK 293-VEC (lane 1), TPalpha -5 (lanes 2 and 3), and TPbeta -17 (lanes 4 and 5) cells were subjected to SDS-PAGE and electrotransferred to nitrocellulose. The membranes were further saturated in Tris-buffered saline buffer, containing 2% BSA. They were incubated with specific antibodies for TPalpha (lanes 1-3) or TPbeta (lanes 4 and 5). Immunoreactivity was revealed as described under "Experimental Procedures." The antisera were preadsorbed with the corresponding peptides prior to the incubation with the membranes in lanes 3 and 5. B, HEK-293 cells or washed human platelets were lysed, and 0.8 mg of total cell protein were immunoprecipitated using the immunoaffinity columns of Abalpha and Abbeta for TPalpha and TPbeta isoforms. Samples were processed as described above. Lanes 1, 3, and 5 correspond to HEK 293-VEC, TPalpha -5, and human platelets, respectively, and were blotted with Abalpha ; lanes 2 and 4 correspond to HEK 293-VEC and TPbeta , respectively, and were blotted with Abbeta .
[View Larger Version of this Image (27K GIF file)]


Membrane Localization of the TP Receptor Isoforms

The antibodies Abalpha and Abbeta recognized the receptors in situ as assessed by immunofluorescence staining of TPalpha -5 and TPbeta -17 clones (Fig. 4, A and C, respectively), Almost all of the cells stained positively for the TPs. Immunofluorescence staining was uniformly distributed over the cell surface. No staining was detected in the absence of Abalpha or Abbeta (Fig. 4, B and D, respectively). Furthermore, no immunofluorescence was observed when anti-peptide antibodies were substituted with nonimmune rabbit serum or when the antibodies were saturated with the corresponding peptides (data not shown).


Fig. 4. Immunofluorescence staining of TPalpha or TPbeta receptor isoforms in HEK 293 cells using specific antibodies. Fixed HEK 293 cells stably overexpressing TPalpha (A and B) or TPbeta (C and D) were blocked in PBS, containing 2% BSA, and incubated with anti-peptide antibodies specific for the TP receptor isoforms. Immunoreactivity was detected using a secondary antibody anti-rabbit coupled to fluorescein isothiocyanate and examined using an fluorescence microscope. The magnification is × 150. TPalpha -5 and TPbeta -17 cells were incubated in the presence (A and C) or absence (B and D) of specific antibodies.
[View Larger Version of this Image (111K GIF file)]


Specific Phosphorylation of Human TPs by U46619

Incubation of [32P]orthophosphate-prelabeled TPalpha -5 or TPbeta -17 with 1 µM U46619 resulted in phosphorylation of a broad radioactive protein band that migrated at the same molecular weight as that of the TP isoforms described above (Fig. 5, A and B, for TPalpha -5 and TPbeta -17, respectively). A very weak signal was detected in the unstimulated cells (Control) or when HEK 293-VEC were incubated with U46619 (data not shown). The increase in U46619-dependent phosphorylation over unstimulated cells was 4-5-fold (n = 12) and 3-4-fold (n = 8) for TPalpha and TPbeta , respectively. Preincubation of the cells with 50 µM SQ29,548 prevented phosphorylation of the TPs, whereas SQ29,548 alone did not induce any phosphorylation. The nature of the weakly phosphorylated band observed in the unstimulated cells is difficult to determine, since preclearing of the cell lysates with the nonimmune rabbit serum eliminated a nonspecific but strongly radioactive doublet that migrates exactly at the same molecular weight as that of TPalpha and TPbeta . Immunoblot analysis of the immunoprecipitated receptors in these samples showed no difference in the quantity of the TP isoforms immunoprecipitated (data not shown). This indicates that the antisera may recognize both the phosphorylated and the unphosphorylated isoforms of the receptors. This is important, since the antibodies are directed against a polypeptide sequence present in the carboxyl-terminal end, where phosphorylation of the receptors may occur (9).


Fig. 5. Specific phosphorylation of thromboxane receptors in vivo following stimulation with U46619. 32P-Labeled TPalpha -5 (A) or TPbeta -17 (B) cells were incubated for 10 min in the presence of 200 nM U46619 with or without 50 µM SQ29,548 for 10 min at 37 °C. The cells were lysed in radioimmune precipitation buffer and precleared with a nonimmune rabbit serum affinity Sepharose column. Supernatants were further immunoprecipitated using the specific TP antibody affinity columns as described under "Experimental Procedures." Samples were subjected to SDS-PAGE, and the gels were dried. The signal was revealed by PhosphorImager analysis. The data are representative of at least three experiments. 66 and 49 correspond to the protein molecular weight markers.
[View Larger Version of this Image (41K GIF file)]


Dose- and Time-dependent Phosphorylation of the TPalpha and the TPbeta Isoforms by U46619

32P-Labeled TPalpha -5 and TPbeta -17 were stimulated with increasing concentrations of U46619 (1-1000 nM). Phosphorylation of the TP isoforms was detectable in TPalpha -5 cells at concentrations as low as 3 nM U46619 and reached a plateau at ~ 100 nM (Fig. 6A). Similar results were obtained for TPbeta -17 cells (Fig. 6B). The EC50 values for U46619 for phosphorylation of the TPalpha and TPbeta isoforms were similar (12 ± 2 nM for TPalpha , n = 3; 11.5 ± 1.3 nM for TPbeta , n = 4) (Fig. 6B). Phosphorylation of the TPalpha and TPbeta (Fig. 7, A and B, respectively) receptors was rapidly (1 min) detected at a saturating concentration of U46619 (300 nM) and reached a plateau at ~ 30 min. Incubation times of up to 90 min resulted in no further change in the phosphorylation pattern. Basal phosphorylation was detected at longer incubation times (>30 min).


Fig. 6. Dose-dependent increase in TP phosphorylation in the presence of the agonist, U46619. 32P-Labeled TPalpha -5 (A) or TPbeta -17 (B) cells were incubated with increasing doses of U46619 (1-1000 nM) or vehicle (control) for 10 min. Immunoprecipitation of the radioactive protein was performed as described in the legend for Fig. 5. Results represent one single experiment. B, three replicates of the experiment for TPalpha -5 cells (bullet ------bullet ) and TPbeta -17 cells (open circle ------open circle ) are summarized. TP receptor phosphorylation is expressed as a percentage of maximal phosphorylation compared with unstimulated cells.
[View Larger Version of this Image (36K GIF file)]



Fig. 7. Kinetics of phosphorylation of the TP isoforms. 32P-Labeled TP alpha -5 (A) or TPbeta -17 (B) cells were incubated for increasing times with U46619 (300 nM). Analysis of phosphorylated TPs was performed as described in the legend for Fig. 5. Unstimulated cells showed higher phosphorylation due to higher incorporation of 32Pi with time. The results presented are from single experiments, each representative of three replicates for TPalpha -5 and two for TPbeta -17.
[View Larger Version of this Image (80K GIF file)]


Effect of Protein Kinase C Inhibition on U46619-dependent Phosphorylation of the TP Isoforms

To study the role of PKC activation in the U46619-dependent phosphorylation of the TP receptors, we first tested the effect of a specific inhibitor of PKC, the bisindolylmaleimide I (GF 109203X) (27). PMA alone (100 nM) induced 2-3-fold phosphorylation of the TPs over unstimulated cells and roughly 2-fold for TPbeta -17. No phosphorylation was observed with 4alpha -PMA, an isomer of PMA that does not activate PKC. Increasing concentrations of GF 109203X (2-10 µM) inhibited the PMA-dependent phosphorylation of the TP isoforms by 70-90% (Fig. 8, A and B). Although high concentrations of GF 109203X reduced basal phosphorylation of the both TP isoforms, they inhibited U46619-dependent phosphorylation by only about 30%. Similar percentages of inhibition were obtained at lower concentrations of U46619. Prolonged preincubation with GF 109203X for up to 2 h or the use of a distinct PKC inhibitor, RO-31-8220 (28), in TPalpha -5 cells gave similar results (data not shown). Furthermore, thrombin (2 units/ml) failed to induce phosphorylation of the TP isoforms, although it did cause a significant increase (80-100 nM) in [Ca2+]i mobilization (data not shown). Similar results were obtained when the cells were transiently transfected with the cDNA for the human thrombin receptor despite a 2-fold increase in thrombin receptor expression as analyzed by flow cytometry using specific anti-peptide antibody against human thrombin receptor (data not shown).


Fig. 8. Agonist-induced phosphorylation of the TP receptor isoforms: effect of PKC inhibition. TPalpha -5 (A) or TPbeta -17 (B) cells were prelabeled with 32Pi and pretreated with increasing doses of the PKC inhibitor, GF 109203X, during the labeling period (45 min). The cells were further stimulated with 1 µM U46619 or 100 nM PMA. Results are from a single experiment representative of three replicates. Inhibition of basal phosphorylation was reduced by ~ 30% in the presence of 5 µM GF 109203X in both cell types (not shown).
[View Larger Version of this Image (78K GIF file)]


PKC down-regulation was accomplished by incubating the cells for 24 h in the presence of PMA (200 nM). Under these conditions, both TPalpha or TPbeta were still phosphorylated by 1 µM U46619, but not by 100 nM PMA (Fig. 9).


Fig. 9. Agonist-dependent phosphorylation of the TP receptors. Effect of down-regulation of PKC. TPalpha -5 (A) or TPbeta -17 (B) cells were incubated for 24 h in the presence of 200 nM PMA to down-regulate PKC. The cells were further washed three times for 5 min with phosphate-free culture media and incubated in the absence or presence of 100 nM PMA or 1 µM U46619. The cells were treated as described under "Experimental Procedures." Equivalent total cpm were used for immunoprecipitation of the cells preincubated with PMA. The single experiments shown are representative of two replicates.
[View Larger Version of this Image (40K GIF file)]


Effect of Protein Kinase A Inhibition on U46619-dependent Phosphorylation of the TP Receptors

Incubation of prelabeled cells with 10 µM FK in the presence of 0.5 mM IBMX resulted in a weak phosphorylation of the TPalpha isoforms. The capacity for PKA-dependent phosphorylation of both TP isoforms was illustrated when Bt2cAMP was incubated for 30 min in the presence of IBMX. The phosphorylation of TPalpha receptors by FK was strongly inhibited by H-89 (29), a competitive inhibitor of PKA (Fig. 10A). Under these conditions, U46619-dependent TP receptor phosphorylation was not inhibited by H-89.


Fig. 10. Effect of PKA inhibition or activation on the phosphorylation of the TP receptor isoforms. TPalpha -5 (A) or TPbeta -17 (B) cells were labeled with [32P]orthophosphate and treated with 50 µM H-89 for 45 min in the presence of 0.5 mM IBMX. The cells were further stimulated with 300 nM U46619 or 10 µM FK for 10 min and treated as indicated in the legend for Fig. 5. Labeled cells were incubated with Bt2cAMP for 30 min to allow maximal activation. The increase in the phosphorylation in this condition should be compared with the control cells obtained at 30 min. The experiments are representative of three replicates for FK and two with Bt2cAMP.
[View Larger Version of this Image (52K GIF file)]


Homologous Desensitization of TP Isoform-mediated Inositol Phosphate Formation

Pretreatment of TPalpha -5 or TPbeta -17 with 300 nM U46619 for 10 min resulted in 70-90% inhibition of IP formation in response to a subsequent addition of U46619 (Fig. 11, A and B). Desensitization was rapid for both receptors, reaching a maximum after 1-2 min of pretreatment (Fig. 11C). Maximal desensitization was observed when pretreating the cells with ~100 nM U46619. Moreover, incubation of cells with 5 µM GF 109203X prior to pretreatment of the cells with U46619 did not modify the pattern of desensitization for either the TPalpha or TPbeta isoform, as assessed by IP formation (Fig. 12, A and B, respectively). Along with these results, the pretreatment of the cells with either 200 nM PMA for 10 min or 0.5 mM Bt2cAMP for 30 min did not modify U46619-mediated IP formation (Table II). Neither PMA or Bt2cAMP pretreatment modified the extent of homologous desensitization of TPs under these conditions.


Fig. 11. Effect of agonist pretreatment on TP receptor function. Subconfluent TPalpha -5 or TPbeta -17 cells in 12 well plates were metabolically labeled with 2 µCi of myo-inositol for 20 h in inositol-free DMEM culture medium. TPalpha -5 (A) or TPbeta -17 (B) cells were incubated for 10 min in the presence (black-triangle, triangle ) or the absence (bullet , open circle ) of 300 nM U46619. They were further washed with glycine buffer, pH 3, and incubated with increasing doses of U46619. C, TPalpha -5 (bullet ) or TPbeta -17 (open circle ) cells were pretreated with 300 nM U46619 for different periods of time and then challenged with 300 nM U46619. Results are the average ± S.E. of three different experiments performed in duplicate.
[View Larger Version of this Image (18K GIF file)]



Fig. 12. Effect of GF 109203X on the desensitization of the TP receptor isoforms. TPalpha -5 (A) or TPbeta -17 (B) cells were incubated for 30 min in the presence or absence of GF 109203X prior to the pretreatment with 300 nM U46619 (Pretreatment U46619) or vehicle (Control) for 10 min. Cells were washed once with glycine buffer, pH 3, for 30 s and further incubated for 10 min with 300 nM U46619 (black bars) or vehicle alone (gray bars). Total inositol phosphates were analyzed, and cells were further processed as indicated under "Experimental Procedures." Results are the average ± S.E. of three different experiments performed in duplicate.
[View Larger Version of this Image (16K GIF file)]


Table II.

Effect of PMA and Bt2cAMP treatment on the U46619-mediated IP formation in HEK-293 TPalpha and TPbeta cells

Cells were treated in the presence or absence of 0.5 mM Bt2cAMP (30 min) or 200 nM PMA (10 min). Cells were washed and then incubated for 10 min in the presence of 300 nM U46619. For desensitization experiments, cells were incubated with vehicle, PMA, or Bt2cAMP prior to the pretreatment with 300 nM U46619. Cells were washed once with glycine buffer, pH 3, for 30 s and further incubated for 10 min with 300 nM U46619. Total inositol phosphate formation was determined as described under "Experimental Procedures." Results represent the mean ± S.E. of three or four different experiments performed in duplicate. Unpaired t test revealed no significant differences between PMA or Bt2cAMP and untreated cells.
Pretreatment Total IP
Desensitization
TPalpha TPbeta TPalpha TPbeta

% of control % of control
Vehicle 673  ± 96 531  ± 40 140  ± 11 150  ± 10
PMA 489  ± 66 433  ± 40 162  ± 7 148  ± 9
Bt2cAMP 566  ± 75 411  ± 70 145  ± 11 148  ± 5


DISCUSSION

TxA2 is an evanescent biological mediator; it exerts potent effects on platelet function and vascular tone in the immediate microenvironment of its formation (18). Given its critical role in determining vascular patency, it would seem likely that its formation and effects would be tightly regulated. TxA2 is not stored, preformed in cells. Rather, it is formed and released rapidly in response to cellular (e.g. platelet) activation by diverse stimuli. Its effects are limited by its hydrolysis to the inactive thromboxane B2, which has a half-life estimated to be 30 s at physiological pH (2) and by homologous desensitization of its membrane receptor-mediated responses (30, 31). This desensitization appears to result initially from uncoupling of the TP from its attendant G proteins; we have previously estimated that the half-life of such a response (coupling to phospholipase C in human platelets) is approximately 120 s. This phenomenon is followed by more gradual loss of binding sites from platelet membranes (30).

A single gene encoding a TP has been cloned (5). This predicts membership of the TPs in the family of GPCRs, consistent with their biochemical characteristics (32). It appears that the TP is subject to alternative splicing in the carboxyl-terminal region, as has been previously described for E prostaglandin receptor type 3 (33). Little is known about the functional significance of this observation. However, pharmacological studies have indicated the possibility of tissue-specific differences in the characteristics of TPs and, indeed, differences in TP binding of ligands within a single cell, platelets (11, 34, 35). Observations involving E prostaglandin receptor carboxyl-terminal isoforms indicate that they are capable of coupling to distinct downstream signaling systems and that they may differ in the rate and extent to which they are subject to homologous desensitization (36). Narumiya and colleagues have recently reported that mRNAs for the two TP isoforms are expressed in human platelets. When the isoforms are overexpressed in COS cells, they may regulate adenylate cyclase activation differentially (10).

Given these observations, we wished to explore the molecular mechanisms that might underlie homologous desensitization of the two TP isoforms. Importantly, they differ in the length and number of potential target residues for phosphorylation (9), raising the possibility of differential tissue responses to TxA2 (e.g. in platelets and the vasculature) based on differential rates of desensitization. To address this possibility and to clarify the role of specific kinases in the desensitization process, we characterized specific, peptide-based antibodies for the two receptors. These confirmed the membrane localization of the two receptor isoforms, as inferred by their sequences.

Interestingly, both isoforms were rapidly phosphorylated following exposure to agonist. The time and dose dependence of this phenomenon seemed similar for the two isoforms. Both isoforms coupled to downstream signaling systems. We focused on phospholipase C-dependent events, since these are thought most relevant to TxA2-mediated platelet aggregation and vasoconstriction (11, 34). Again the TP agonist, U46619, could stimulate an increase in [Ca2+]i and total inositol phosphates via both isoforms. However, the pattern of the calcium response evoked via the two isoforms appeared to differ, at least in the stable cell lines that we established. Thus, whereas U46619 induced a rapid transient, followed by a delayed plateau in cells expressing TPalpha , the plateau phase was almost absent in the cells expressing TPbeta . Activation of both isoforms appeared to involve release of calcium from intracellular stores. However, the plateau phase of the TPalpha response appeared to derive from an extracellular source, raising the possibility of linkage to a receptor-activated calcium channel (37). Further experiments will address this possibility and whether a similar distinction is evident in other cells transfected with the two isoforms.

Given the role of phospholipase C-mediated responses in the biological consequences of TP activation, it would seem likely that downstream activation of PKC might play a central role in homologous desensitization. Indeed, we have previously shown that PKC may phosphorylate a fusion protein based on the carboxyl-terminal end of the TPalpha receptor (residues 321-343) in vitro (19). Peptide competition experiments suggested that this involved sites in the third extracellular loop and the carboxyl-terminal tail (19). Okwu et al. (20) have recently presented data consistent with TP phosphorylation in human platelets. Phosphorylation plays an important role in regulating both homologous and heterologous desensitization of GPCRs like the TPs. Additionally, other serine/threonine kinases such as PKA, G protein-coupled receptor-dependent kinases, and tyrosine kinases have been implicated in GPCR phosphorylation (38-40). We have demonstrated that PKA may phosphorylate TPalpha to a minor degree in vitro (19). Similarly, we demonstrate the capacity for PKA to phosphorylate the receptor in the present study in vivo. However, PKA appears to contribute trivially, if at all, to rapid phosphorylation of the TPs induced by U46619. Although there is no information on G protein-coupled receptor-dependent kinase-mediated phosphorylation of eicosanoid receptors, recent studies have demonstrated their ability to phosphorylate angiotensin and adrenoreceptor GPCRs (41, 42).

We also demonstrate that PKC appears to play a modest role in agonist-dependent phosphorylation of either TP isoform. Thus, two specific competitive inhibitors of PKC, GF 109203X and RO 31-8220, failed to modify the rate or extent of agonist-stimulated phosphorylation of either isoform. Similarly, down-regulation of PKC, by prolonged exposure to the phorbol ester, PMA, also failed to alter these phenomena. We demonstrate that homologous desensitization of agonist-evoked increases in IPs is similar for both isoforms. Again, the PKC inhibitor, GF 109203X, failed to modify homologous desensitization of this response evoked via either isoform. Although PKC appears largely irrelevant to the agonist-mediated desensitization response, activation of this enzyme may phosphorylate TPs. Thus, short term exposure to PMA will result in phosphorylation of both isoforms. However, treatment of the cells with thrombin (2 units/ml) did not induce phosphorylation of the TPs, although cells were activated, as assessed by [Ca2+]i mobilization. Transient co- expression of the human thrombin receptor and stimulation with thrombin did not result in the phosphorylation of the TP receptor isoforms. Similarly, we have recently shown that phosphorylation of the prostacyclin receptor (43) can be induced by thrombin in a PKC-dependent manner, confirming that the endogenous thrombin receptor in HEK-293 cells is sufficient to mediate PKC-dependent phosphorylation of a related GPCR.

In contrast to agonist-dependent phosphorylation, the PKC inhibitors appeared to diminish basal phosphorylation of both isoforms.

Similar to our findings with PKC, PKA appeared to be of trivial relevance to agonist-dependent phosphorylation of either isoform. Both FK and Bt2cAMP treatment of the stable transfectants resulted in phosphorylation of both isoforms under favorable conditions (i.e. pharmacological inhibition of phosphodiesterases), extending our previous in vitro observations (19). However, the PKA inhibitor, H-89, had no apparent effect on U46619-induced phosphorylation of either isoform. Although U46619 is a potent stimulus to phospholipase C activation, higher concentrations may also activate adenylate cyclase (10). However, these concentrations do not appear to result in TP phosphorylation by PKA in vivo. It is likely that, as with PKC, activation of this enzyme might assume more importance in TP phosphorylation during heterologous desensitization.

The use of our antibodies identified TPs as a broad band ranging from 55 to 65 kDa. This molecular mass is somewhat higher than that previously observed by others in human platelets (44, 45). Indeed, we identified a 45-50-kDa protein when we immunoprecipitate human platelet TP receptors with Abalpha (Fig. 3B, lane 5). This may reflect different degrees of glycosylation or palmitoylation (46) of TP isoforms in HEK-293 cells compared with platelets. Interestingly, the molecular weight of the phosphorylated protein is similar to that in the immunoblot analysis. The TP antagonist prevents phosphorylation of that band, further confirming its identity.

In conclusion, we have demonstrated that the rate and extent of agonist-dependent phosphorylation of the two cloned TP isoforms is similar, although their coupling to [Ca2+]i and IP formation is somewhat different. Neither PKC nor PKA plays a major role in such phosphorylation of either isoform, implicating the G protein-coupled receptor-dependent kinases in homologous desensitization of these receptors. However, both TP isoforms are substrates for PKC and PKA in vivo, and these enzymes may play a more important role in their heterologous desensitization or in receptor regulation in other cells. The availability of specific antibodies for TP isoforms is likely to facilitate investigation of their comparative distribution and biology.


FOOTNOTES

*   This work is supported by National Institutes of Health Grant HL 5600 and the Ministère de l'Education Nationale by Grant ACC-SV9.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
par    Robinette Foundation Professor of Cardiovascular Medicine. To whom correspondence should be addressed: Center for Experimental Therapeutics, 905 Stellar-Chance Laboratories, University of Pennsylvania, 422 Curie Blvd., Philadelphia, PA 19104. Tel.: 215-898-7056; Fax: 215-573-8996; E-mail: garret{at}spirit.gcrc.upenn.edu.
1   The abbreviations used are: TxA2, thromboxane A2; GPCR, G protein-coupled receptor; Ab, antibody; BSA, bovine serum albumin; Bt2cAMP, dibutyryl cAMP; FK, forskolin; HEK, human embryonic kidney; IBMX, 3-isobutyl-1-methylxanthine; IP, total inositol phosphate; PKC, protein kinase C; PKA, protein kinase A; PMA, phorbol 12-myristate 13-acetate; TP, thromboxane receptor; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline.

Acknowledgments

We are grateful for the help of Dr. Yu-Min Shen in preparing the stable transfected cells and Maryline Lebret for a contribution in the development of antisera. We thank Dr. Marina Molino and Peter O'Brien for help in performing the Ca2+ experiments and the flow cytometry of the thrombin receptor and Drs. Ellen Van Obberghen-Schilling and Lawrence Brass for helpful advice.


REFERENCES

  1. Smith, W. L. (1992) Am J. Physiol. 263, F181-F191 [Abstract/Free Full Text]
  2. Hamberg, M., Svensson, J., and Samuelsson, B. (1975) Proc. Natl. Acad. Sci. U. S. A. 72, 2994-2998 [Abstract]
  3. FitzGerald, G. A. (1991) Am. J. Cardiol. 68, 11B-15B [Medline] [Order article via Infotrieve]
  4. Morinelli, T. A., and Halushka, P. V. (1991) Trends Cardiovasc. Med. 4, 157-161
  5. Nüsing, R. M., Hirata, M., Kakizuka, A., Eki, T., Ozawa, K., and Narumiya, S. (1993) J. Biol. Chem. 268, 25253-25259 [Abstract/Free Full Text]
  6. Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S., and Narumiya, S. (1991) Nature 349, 617-620 [CrossRef][Medline] [Order article via Infotrieve]
  7. D'Angelo, D. D., Davos, M. G., Ali, S., and Dorn, G. W., II (1994) J. Pharmacol. Exp. Ther. 271, 1034-1041 [Abstract]
  8. Allan, C. J., Higuashiuri, K., Martin, T., Morinelli, T. A., Kurtz, D. T., Geoffrey, O., Meier, G. M., Gettys, T. W., and Halushka, P. V. (1996) J. Pharmacol. Exp. Ther. 277, 1132-1139 [Abstract]
  9. Raychowdhury, M. K., Yukawa, M., Collins, L. J., McGrail, S. H., Kent, C., and Ware, J. A. (1994) J. Biol. Chem. 269, 19256-19261 [Abstract/Free Full Text] ; Correction (1995) J. Biol. Chem. 270, 7011
  10. Hirata, T., Ushikubi, F., Kakizuka, A., Okuma, M., and Narumiya, S. (1996) J. Clin. Invest. 97, 949-956 [Abstract/Free Full Text]
  11. Takahara, K., Murray, R., FitzGerald, G. A., and Fitzgerald, D. J. (1990) J. Biol. Chem. 265, 6836-6844 [Abstract/Free Full Text]
  12. Zucker, T-P., Bönisch, D., and Schrör, K. (1995) Circulation 92, I-111 (Abstr. 0522)
  13. Sachinidis, A., Flesch, M., Ko, Y., Schrör, K., Böhm, M., Düsing, R., and Vetter, H. (1995) J. Hypertension 26, 771-780
  14. Morinelli, T. A., Zhang, L-M., Newman, W. H., and Meier, K. E. (1994) J. Biol. Chem. 269, 5693-5698 [Abstract/Free Full Text]
  15. Ali, S., Davis, M. G., Becker, M. W., and Dorn, G. W., II (1993) J. Biol. Chem. 268, 17397-17403 [Abstract/Free Full Text]
  16. Jones, D., Benjamin, C. W., and Linseman, D. A. (1995) Mol. Pharmacol. 48, 890-896 [Abstract]
  17. Murray, R., Shipp, E., and FitzGerald, G. A. (1990) J. Biol. Chem. 265, 21670-21675 [Abstract/Free Full Text]
  18. Halushka, P. V., Allan, C. J., and Davis-Bruno, K. (1995) J. Lipid Mediators 12, 361-378 [CrossRef]
  19. Kinsella, B. T., O'Mahony, D. J., and FitzGerald, G. A. (1994) J. Biol. Chem. 269, 29914-29919 [Abstract/Free Full Text]
  20. Okwu, A. K., Mais, D. E., and Halushka, P. V. (1994) Biochim. Biophys. Acta 1221, 83-88 [Medline] [Order article via Infotrieve]
  21. Coleman, R. A., Humphrey, P. P., Kennedy, I., Levy, G. P., and Lumley, P. (1981) Br. J. Pharmacol. 73, 773-778 [Abstract]
  22. Praticò, D., Smyth, E. M., Violi, F., and FitzGerald, G. A. (1996) J. Biol. Chem. 271, 14916-14924 [Abstract/Free Full Text]
  23. Seuwen, K., Lagarde, A., and Pouyssegur, J. (1988) EMBO J. 7, 161-168 [Abstract]
  24. Woolkalis, M. J., DeMelfi, T. M., Jr., Blanchard, N., Hoxie, J. A., and Brass, L. F. (1995) J. Biol. Chem. 270, 9868-9875 [Abstract/Free Full Text]
  25. Créminon, C., Habib, A., Flobert, Y., Maclouf, J., Grassi, J., Pradelles, P., and Flobert, Y. (1995) Biochim. Biophys. Acta. 1254, 341-334 [Medline] [Order article via Infotrieve]
  26. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1995) Current Protocols in Molecular Biology: Analysis of Protein Phosphorylation, John Wiley & Sons, Inc., New York
  27. Martiny-Baron, G., Kazanietz, M. G., Mischak, H., Blumberg, P. M., Kochs, G., Hug, H., Marme, D., and Schächtele, C. (1993) J. Biol. Chem. 268, 9194-9197 [Abstract/Free Full Text]
  28. Davis, P. D., Elliott, L. H., Harris, W., Hill, C. H., Hurst, S. A., Keech, E., Kumar, M. K. H., Lawton, G., Nixon, J. S., and Wilkinson, S. E. (1992) J. Med. Chem. 35, 994-1001 [Medline] [Order article via Infotrieve]
  29. Chijiwa, T., Mishima, A., Hagiwara, M., Sano, M., Hayashi, K., Inoue, T., Naito, K., Toshioka, T., and Hidaka, H. (1990) J. Biol. Chem. 265, 5267-5272 [Abstract/Free Full Text]
  30. Murray, R., and FitzGerald, G. A. (1989) Proc. Natl. Acad. Sci. U. S. A. 89, 124-128
  31. Okwu, A. K., Ullian, M. E., and Halushka, P. V. (1992) J. Pharmacol. Exp. Ther. 262, 238-245 [Abstract]
  32. Ushikubi, F., Hirata, M., and Narumiya, S. (1995) J. Lipid Mediators 12, 343-359 [CrossRef]
  33. Kotani, M., Tanaka, I., Ogawa, Y., Mori, K., Ichikawa, A., Narumiya, S., Yoshimi, T., and Nakao, K. (1995) Mol. Pharmacol. 48, 869-879 [Abstract]
  34. Furci, L., Fitzgerald, D. J., and FitzGerald, G. A. (1991) J. Pharmacol. Exp. Ther. 258, 74-81 [Abstract]
  35. Dorn, G. W., Jr. (1991) Am. J. Physiol. 261, R145-R153 [Abstract/Free Full Text]
  36. Negishi, M., Namba, T., Sugimoto, Y., Irie, A., Katada, T., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 26067-26070 [Abstract/Free Full Text]
  37. Felder, C. C., Singer-Lahat, D., and Mathes, C. (1994) Biochem. Pharmacol. 48, 1997-2004 [Medline] [Order article via Infotrieve]
  38. Benovic, J. L., Bouvier, M., Caron, M. G., and Lefkowitz, R. J. (1988) Annu. Rev. Cell Biol. 4, 405-428 [CrossRef]
  39. Gomez, J., and Benovic, J. L. (1992) Int. Rev. Cytol. 137B, 1-34 [Medline] [Order article via Infotrieve]
  40. Baltensperger, K., Karoor, V., Paul, H., Ruoho, A., Czech, M. P., and Malbon, C. C. (1996) J. Biol. Chem. 271, 1061-1064 [Abstract/Free Full Text]
  41. Oppermann, M., Freedman, N. J., Alexander, R. W., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 13266-13272 [Abstract/Free Full Text]
  42. Diviani, D., Lattion, A-L., Larbi, N., Kunapuli, P., Pronin, A., Benovic, J. L., and Cotecchia, S. (1996) J. Biol. Chem. 271, 5049-5058 [Abstract/Free Full Text]
  43. Smyth, E. M., Nestor, P. V., and FitzGerald, G. A. (1996) J. Biol. Chem. 271, 33698-33704 [Abstract/Free Full Text]
  44. Ushikubi, F., Nakajima, M., Hirata, M., Okuma, M., Fujiwara, M., and Narumiya, S. (1989) J. Biol. Chem. 264, 16496-16501 [Abstract/Free Full Text]
  45. Borg, C., Lim, C. T., Yeomans, D. C., Dieter, J. P., Komiotis, D., Anderson, E. G., and Le Breton, G. C. (1994) J. Biol. Chem. 269, 6109-6116 [Abstract/Free Full Text]
  46. Bouvier, M., Loisel, T. P., and Hebert, T. (1995) Biochem. Soc. Trans. 23, 577-581 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.